Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paliperidone extended release.

Lily P H Yang1, Greg L Plosker

  • 1Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|April 24, 2007
PubMed
Summary
This summary is machine-generated.

Paliperidone extended release (ER) effectively treats schizophrenia symptoms in adults, including the elderly. This oral antipsychotic demonstrated significant improvements in functioning and reduced symptom recurrence compared to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An implementation study of text invitation, mailed at-home human papillomavirus (HPV) self-testing and telehealth management in Aotearoa New Zealand, with a nested randomised controlled trial that compared offering an incentive vs. no offer with a repeat test kit.

BMC public health·2026
Same author

Demographic profile of potential target populations in community laboratory and emergency department settings for consideration in expanding hepatitis C screening in Aotearoa New Zealand.

Journal of primary health care·2026
Same author

The role of community pharmacies in the provision of human papillomavirus (HPV) self-testing: A range of delivery models and proof-of-concept study.

Exploratory research in clinical and social pharmacy·2026
Same author

Clinician and patient experiences with opportunistic offer of HPV self-testing in Aotearoa New Zealand primary care clinics: interview and survey findings.

BMC primary care·2026
Same author

Opportunistic offer of human papillomavirus (HPV) self-testing in ethnically diverse primary care clinics in Aotearoa New Zealand: an implementation study.

BMC primary care·2025
Same author

Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis.

CNS drugs·2020
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia is a chronic mental disorder characterized by positive and negative symptoms.
  • Consistent plasma drug concentrations are crucial for effective antipsychotic treatment.
  • Paliperidone extended release (ER) offers a once-daily oral administration for schizophrenia management.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of paliperidone ER in adult patients with schizophrenia.
  • To assess the impact of paliperidone ER on positive and negative symptoms.
  • To determine the effect of paliperidone ER on personal and social functioning and disease severity.

Main Methods:

  • Four well-controlled trials assessed once-daily paliperidone ER (3-12 mg) over 6 weeks against placebo.

Related Experiment Videos

  • Efficacy was measured by symptom reduction, personal and social functioning, and disease severity.
  • A separate trial investigated the prevention of schizophrenia symptom recurrence.

    • Main Results:

    • Paliperidone ER significantly reduced positive and negative symptoms of schizophrenia compared to placebo.
    • Patients on paliperidone ER showed greater improvements in functioning and disease severity.
    • Paliperidone ER demonstrated superior efficacy in preventing symptom recurrence and delaying time to recurrence.

    Conclusions:

    • Once-daily paliperidone ER is an effective treatment for schizophrenia in adults, including the elderly.
    • Paliperidone ER improves clinical outcomes and personal/social functioning.
    • The medication is generally well-tolerated and effective in preventing symptom recurrence.